Placental Transfer of Sugammadex in the Human Placental Perfusion Model

Placental Transfer of Sugammadex in the Human Placental Perfusion Model

Preclinical research raised concern regarding the foetal effects of using sugammadex during pregnancy. However, to the best of our knowledge, the placental transfer of sugammadex has never been measured. As these data would be critical in assessing the foetal effects after maternal administration of sugammadex, it is warranted to measure the placental transfer of sugammadex. The aim of this project is to measure the placental transfer of sugammadex in the human placenta by using the ex vivo human placenta perfusion model.

Inclusion Criteria:

• informed consent signed
• (placenta of a) pregnant women with an uncomplicated pregnancy and delivery

Exclusion Criteria:

• chronic medication use during pregnancy
• maternal diseases during pregnancy (including diabetes mellitus, hypertension, thyroid dysfunction), or any infection (chorioamnionitis and toxoplasmosis, other, rubella, cytomegalovirus, herpes infections, or a positive anti-HIV, anti-hepatitis B virus, or anti-hepatitis C virus serology)